Log In
BCIQ
Print this Print this
 

Zydelig, idelalisib (formerly CAL-101, GS 1101, GS-1101)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionSmall molecule inhibitor of phosphoinositide 3-kinase (PI3K) delta
Molecular Target Phosphoinositide 3-kinase (PI3K) delta
Mechanism of ActionPhosphoinositide 3-kinase (PI3K) delta inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$600.0M

$375.0M

$225.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/01/2011

$600.0M

$375.0M

$225.0M

Get a free BioCentury trial today